Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [31] Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2
    Cui, Yetong
    Wang, Ruonan
    Wei, Yujiao
    Hou, Fei
    Li, Haixi
    Jiang, Yurui
    Sun, Yue
    Fu, Shushu
    Zuo, Lina
    Wang, Xiaoji
    Li, Ming
    Li, Jinling
    Liu, Ning
    Zhang, Kun
    Wei, Mingming
    Yang, Guang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 81
  • [32] HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations
    Zhou, Caicun
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Su, Chunxia
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S705 - S705
  • [33] Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors
    Carlsson, J.
    Shen, L.
    Xiang, J.
    Xu, J.
    Wei, Q.
    ONCOLOGY LETTERS, 2013, 5 (01) : 208 - 214
  • [34] EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
    Xu, Jian Ming
    Han, Yu
    Duan, Hai Qing
    Gao, E. Mei
    Zhang, Yang
    Liu, Xiao Qing
    Zhang, Jing Sheng
    Toschi, Luca
    Galetta, Domenico
    Azzariti, Amalia
    Paradiso, Angelo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 771 - 782
  • [35] HER2, EGFR AND TOPIIA GENE AMPLIFICATION AND PROTEIN EXPRESSION IN SYNOVIAL SARCOMA BEFORE AND AFTER COMBINED TREATMENT
    Ptaszynski, Konrad
    Szumera-Cieckiewicz, Anna
    Zakrzewska, Klara
    Tuziak, Tomasz
    Mrozkowiak, Anna
    Rutkowski, Piotr
    POLISH JOURNAL OF PATHOLOGY, 2009, 60 (01) : 10 - 18
  • [36] The expression of EGFR, HER2 and EpCam in Head and Neck squamous cell carcinomas
    Schartinger V.H.
    Schmutzhard J.
    Wurm M.
    Schwentner I.M.
    Obrist P.
    Oberaigner W.
    Sprinzl G.M.
    memo - Magazine of European Medical Oncology, 2009, 2 (1) : 45 - 50
  • [37] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
    Nagasaka, Misako
    Singh, Vijendra
    Baca, Yasmine
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Uprety, Dipesh
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Oberley, Matthew
    Feldman, Rebecca
    Xiu, Joanne
    Korn, W. Michael
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
  • [38] Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization
    Baek, Kwang Hyun
    Hong, Min Eui
    Jung, Yoon Yang
    Lee, Chung Hun
    Lee, Tae Jin
    Park, Eon Sub
    Kim, Mi Kyung
    Yoo, Jae Hyung
    Lee, Soo Whan
    CANCER RESEARCH AND TREATMENT, 2012, 44 (01): : 50 - 56
  • [39] Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
    Yamada, Yutaka
    Imai, Hisao
    Sugiyama, Tomohide
    Minemura, Hiroyuki
    Kanazawa, Kenya
    Kasai, Takashi
    Minato, Koichi
    Kaira, Kyoichi
    Kaburagi, Takayuki
    MEDICINA-LITHUANIA, 2021, 57 (09):
  • [40] HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
    Eriksson, Pontus
    Sjodahl, Gottfrid
    Chebil, Gunilla
    Liedberg, Fredrik
    Hoglund, Mattias
    ONCOTARGET, 2017, 8 (30) : 48905 - 48914